Arabic Arabic English English French French German German
dark

Novartis Inks $1.35 Billion Deal with Mesoblast for Remestemcel-L for COVID-19 ARDS

Novartis inked an exclusive worldwide license and collaboration deal with Australia-based Mesoblast to develop, commercialize and manufacture remestemcel-L for acute respiratory distress syndrome (ARDS), including when it is linked to COVID-19. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Comparison of nonhuman primates identified the suitable model for COVID-19

Next Post

Newfound ability to change baby brain activity could lead to rehabilitation for injured brains

Related Posts
Total
0
Share